Industry News
Excerpt from the Press Release: MENLO PARK, Calif., July 14, 2021 (GLOBE NEWSWIRE) — CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced an update on the timing for the release of the data for its Phase 1a/1b clinical study of…
Read More
Excerpt from the Press Release: MADRID, Spain and CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that it has received approval from the Spanish Drug Agency (AEMPS) for its Clinical…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., July 13, 2021 /PRNewswire/ — Artax Biopharma, Inc., a biotechnology company focused on transforming the treatment of T Cell-mediated diseases, today announced that the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted clinical trial authorization to evaluate AX-158 in a Phase 1 clinical trial for the treatment of T Cell-Mediated Diseases.…
Read More
Excerpt from the Press Release: Echocardiography parameters and ARDS linked to higher mortality risk for hospitalized patients. Transthoracic echocardiography (TTE) plays a role in pinpointing the risk a COVID-19-positive patient has of dying. In a study published July 21 in the European Journal of Clinical Investigation, a team of investigators from Italy determined that left ventricular ejection…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Immunicom, Inc., a clinical stage biotech, shared preliminary data from its metastatic triple-negative breast cancer (mTNBC) clinical trial with its novel breakthrough Immunopheresis® therapy at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021. Immunicom’s subtractive immunotherapies are designed to remove immune inhibitors and enhance patients natural immune…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass.–(BUSINESS WIRE)–Q-State Biosciences (“Q-State”), a discovery technology and therapeutics company advancing programs for the treatment of epilepsy, pain, and other disorders of the central nervous system,today announced it has been awarded a non-dilutive grant of $1.3 million from the National Cancer Institute (NCI) of the National Institutes of Health (NIH)…
Read More
Excerpt from the Press Release: WOBURN, Mass.–(BUSINESS WIRE)–IM Therapeutics, a clinical-stage company developing first-in-class human leukocyte antigen (HLA)-targeted therapies to treat autoimmune diseases, today announced positive results on safety, tolerability, pharmacokinetics (PK) and mechanistic action in a Phase 1b study of IMT-002 in patients with type 1 diabetes (T1D). The study, a first for the…
Read More
Excerpt from the Press Release: REDWOOD CITY, Calif.–(BUSINESS WIRE)–Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent serious viral respiratory infections, announced today the release of preclinical data in nonhuman primates (NHPs) of the company’s intranasal recombinant live attenuated COVID-19 vaccine (MV-014-212). The data demonstrate that a single adjuvant-free dose of MV-014-212 provided equivalent protection against SARS-CoV-2…
Read More
Excerpt from the Press Release: SPRINGFIELD, Mo. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Fight Colorectal Cancer (Fight CRC), the nation’s leading colorectal cancer (CRC) patient advocacy organization, and Guardant Health, Inc. (Nasdaq: GH), a leader in precision oncology, will be recognizing clinical researchers and advocates who have demonstrated exceptional leadership during the pandemic in getting people back…
Read More
Excerpt from the Press Release: CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that multiple participants have initiated dosing in the Phase 1b/2a FOCUS-C9 clinical trial evaluating WVE-004 as an investigational treatment…
Read More